Prokidney CORP 10-Q quarterly reports

ProKidney Corp. reported a net loss of $28.4 million for Q2 2026, with significant increases in R&D expenses and substantial doubt raised about its ability to continue as a going concern.

ProKidney Corp. reported a net loss of $20.0 million for the first quarter of 2026, with research and development expenses increasing significantly due to ongoing Phase 3 clinical trials.

ProKidney Corp. announced its third-quarter 2025 financial results, highlighting positive Phase 2 trial data for rilparencel and FDA alignment on its Phase 3 accelerated approval pathway, despite continued net losses and a need for future funding.

ProKidney reports positive Phase 2 trial results for rilparencel and secures FDA clarity for its pivotal Phase 3 study, extending cash runway into mid-2027.

ProKidney Corp. announces its Q1 2025 financial results, highlighting a refined clinical trial strategy focusing on the PROACT 1 trial for potential accelerated FDA approval of rilparencel.

ProKidney Corp. reports its financial results for the third quarter of 2024, including a net loss, and provides an update on its clinical trial strategy for rilparencel.

ProKidney Corp. released its second quarter 2024 financial results, highlighting progress in clinical trials and a recent capital raise.

ProKidney Corp. announced its financial results for the first quarter of 2024, highlighting ongoing clinical development and a focus on a subset of patients for its Phase 3 trial.